Saleem Ansari, Tina Mazaheri, Karen O'Donnell, Matthew Waite, Alexandra Cann, Mariana Abdel-Malek, Luke Boyle, Lucy Tweedlie, Samantha Scholtz, Saira Hameed, Chioma Izzi-Engbeaya, Harvinder Chahal, Tricia Tan
Obesity affects 1 in 4 people in the United Kingdom and costs the National Health Service (NHS) ∼£6.5 billion annually. The glucagon-like peptide-1 (GLP-1) receptor analogues, such as once-daily subcutaneous Liraglutide 3.0 mg (Saxenda®) and once-weekly subcutaneous Semaglutide 2.4 mg (Wegovy®), were approved by the National Institute of Clinical Excellence (NICE) as a treatment for obesity and funded by the NHS for 2 years. Our local data shows that Saxenda is effective at reducing bodyweight and glycaemia in people with obesity and diabetes however, the supply issues of GLP-1 receptor analogues has contributed to the unavailability of Saxenda and Wegovy in our service...
April 19, 2024: Clinical Medicine: Journal of the Royal College of Physicians of London